<table>
<thead>
<tr>
<th>CHAPTER II</th>
<th>REVIEW OF LITERATURE</th>
<th>PAGE NO.</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>JAPANESE ENCEPHALITIS VIRUS</td>
<td>5-26</td>
</tr>
<tr>
<td>2.1.1</td>
<td>Distribution</td>
<td>6</td>
</tr>
<tr>
<td>2.1.1.1</td>
<td>Global scenario</td>
<td>6</td>
</tr>
<tr>
<td>2.1.1.2</td>
<td>Indian scenario</td>
<td>7</td>
</tr>
<tr>
<td>2.1.2</td>
<td>Origin and evolution</td>
<td>9</td>
</tr>
<tr>
<td>2.1.3</td>
<td>Clinical manifestation</td>
<td>12</td>
</tr>
<tr>
<td>2.1.4</td>
<td>Pathogenesis</td>
<td>13</td>
</tr>
<tr>
<td>2.1.5</td>
<td>Histopathology</td>
<td>15</td>
</tr>
<tr>
<td>2.1.6</td>
<td>Enzoonotic cycle</td>
<td>15</td>
</tr>
<tr>
<td>2.1.6.1</td>
<td>Vectors of JEV</td>
<td>15</td>
</tr>
<tr>
<td>2.1.6.2</td>
<td>Host</td>
<td>17</td>
</tr>
<tr>
<td>2.1.7</td>
<td>Socio-economic impact</td>
<td>18</td>
</tr>
<tr>
<td>2.1.8</td>
<td>Molecular biology of JEV</td>
<td>18</td>
</tr>
<tr>
<td>2.1.9</td>
<td>Replication cycle</td>
<td>20</td>
</tr>
<tr>
<td>2.1.10</td>
<td>Current vaccines against JE</td>
<td>22</td>
</tr>
<tr>
<td>2.2</td>
<td>CHIKUNGUNYA VIRUS</td>
<td>27-41</td>
</tr>
<tr>
<td>2.2.1</td>
<td>Epidemiology and natural history</td>
<td>27</td>
</tr>
<tr>
<td>2.2.2</td>
<td>Origin and evolution</td>
<td>30</td>
</tr>
<tr>
<td>2.2.3</td>
<td>Clinical manifestation</td>
<td>31</td>
</tr>
<tr>
<td>2.2.4</td>
<td>Pathogenesis</td>
<td>33</td>
</tr>
<tr>
<td>2.2.5</td>
<td>CHIKV transmission cycle</td>
<td>34</td>
</tr>
<tr>
<td>2.2.5.1</td>
<td>Vectors</td>
<td>34</td>
</tr>
<tr>
<td>2.2.5.2</td>
<td>Host</td>
<td>35</td>
</tr>
<tr>
<td>2.2.6</td>
<td>Molecular biology of CHIKV</td>
<td>36</td>
</tr>
<tr>
<td>2.2.7</td>
<td>Replication cycle</td>
<td>37</td>
</tr>
<tr>
<td>2.2.8</td>
<td>Vaccine and antiviral development</td>
<td>39</td>
</tr>
</tbody>
</table>
CHAPTER III  AIMS AND OBJECTIVES  42

CHAPTER IV  MATERIALS AND METHODS  43-80

4.1  MATERIALS USED  43

4.1.1  ELISA reagents  43

4.1.2  Molecular biology reagents and solutions  45

4.1.3  Cell culture reagents/materials  47

4.1.4  Hemagglutination inhibition test reagents/solutions  48

4.1.5  Kits  50

4.1.6  List of primers used for RT-PCR and sequencing of JEV genome  51

4.1.7  List of primers used for RT-PCR and sequencing of CHIKV genome  52

4.2  STUDY AREA  53

4.3  STUDIES ON JAPANESE ENCEPHALITIS VIRUS (JEV)  53-72

4.3.1  Vaccination programme for JE  53

4.3.2  Patients and clinical specimens  54

4.3.3  Sample preparation  54

4.3.4  Detection of viral aetiology  55

4.3.4.1  Serological detection  55

4.3.4.2  Molecular detection  57

  RNA extraction  57

  Reverse transcriptase PCR  59

4.3.5  Cell-lines and tissue culture  59

4.3.5.1  Cell lines used  59

4.3.5.2  Cell maintenance  60

4.3.5.3  Cell stock freezing and resuscitation  60
4.3.6 Virus infection

4.3.6.1 Virus strain used

4.3.6.2 Preparation of virus stock

4.3.6.3 Plaque assay

4.3.6.4 Isolation of virus

4.3.7 Sequencing of viral genome

4.3.8 Bioinformatics studies

4.3.9 Hemagglutination Inhibition test

4.3.10 Statistical analysis

4.4 STUDIES ON CHIKUNGUNYA VIRUS (CHIKV)

4.4.1 Patients and clinical specimens

4.4.2 Sample preparation

4.4.3 Detection of viral aetiology

4.4.3.1 Serological detection

4.4.3.2 Molecular detection

RNA extraction
Reverse transcriptase PCR

4.4.4 Cell-lines and tissue culture

4.4.4.1 Cell lines used

4.4.4.2 Cell maintenance

4.4.4.3 Cell stock freezing and resuscitation

4.4.5 Virus infection

4.4.5.1 Virus strain used

4.4.5.2 Preparation of virus stock

4.4.5.3 Plaque assay

4.4.5.4 Isolation of virus

4.4.6 Sequencing of viral genome

4.4.7 Bioinformatics studies

4.4.8 Statistical analysis

CHAPTER V RESULTS

81-145
5.1 Japanese encephalitis

IgM result 81
RT-PCR result 82
Yearly distribution 83-84
Age & gender wise distribution 85-87
District wise distribution 88-90
Distribution against socio-economic status and environmental factor 91-93
Month wise distribution 94
Hemagglutination Inhibition test 95-97
Tissue culture 98-99
Sequencing and phylogenetic analysis 100-105

5.2 Chikungunya

5.2.1 Monotypic Chikungunya infection study

IgM result 106
RT-PCR result 107
Yearly distribution 108
District wise distribution 110-112
Age group & gender wise distribution 113-114
Month wise distribution 115
Tissue culture 116
Sequencing and phylogenetic analysis 117-128

5.2.2 Dual infection study

Yearly distribution 129-139
Comparison of demographic features between monotypic and dual infection 134
Age wise distribution 135
Month wise distribution 136
District wise distribution 137
Comparison of clinical characteristics between monotypic and dual infection 138
5.2.3 CNS involvement in CHIKV infection 140-145

CHAPTER VI DISCUSSION 146-159

CHAPTER VII SUMMARY AND CONCLUSION 160-167

BIBLIOGRAPHY

Annexure I

Annexure II